No Image

New tentative approval for Amneal Pharms drug saxagliptin

January 4, 2023 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

January 4, 2023 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

19 physicians elected to Congress

January 3, 2023 AutoBot 0

There are 19 physicians who were elected to Congress in November, including four senators and 15 representatives, the American Medical Association’s Patients Action Network reported […]

Healthcare, Meet Southwest

January 3, 2023 AutoBot 0

BY KIM BELLARD Customers experiencing long, often inexplicable delays, their experiences turning from hopeful to angry to afraid they’ll never get back home.  Staff overworked […]

The end-of-life care conundrum

January 3, 2023 AutoBot 0

Research advises against aggressive cancer treatment at the end-of-life stages of the disease. At the same time, the pharmaceutical industry is creating a greater number […]

No Image

Webinar on BPCIA

January 3, 2023 AutoBot 0

Strafford will be offering a webinar entitled "Biologics Price Competition and Innovation Act: Purple Book, Dispute Resolution, Exclusivities, and Court Treatment" on January 5, 2023 […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

January 3, 2023 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

January 3, 2023 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]